Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation - Case report

Pediatric Transplantation

Volumn 15, Issue 6, 2011, Pages

  Grenda, Ryszard ^a   Jarmuzek, Wioletta ^a   Piatosa, Barbara ^a   Rubik, Jacek ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

nephrotic syndrome; plasmapheresis dependent rituximab; post transplant recurrence

Indexed keywords

CD19 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID;

ARTICLE; B LYMPHOCYTE; CASE REPORT; CHILD; CLINICAL PRACTICE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LONG TERM EXPOSURE; MALE; NEPHROTIC SYNDROME; PATIENT COMPLIANCE; PLASMAPHERESIS; PRESCHOOL CHILD; PROTEINURIA; REMISSION; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD; CYCLOPHOSPHAMIDE; CYCLOSPORINE; HLA ANTIGENS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEPHROTIC SYNDROME; PERITONEAL DIALYSIS; PLASMAPHERESIS; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052091491     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2010.01303.x     Document Type: Article

References (28)

1. Savin V, Sharma R, Sharma M, et al., Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996: 334: 878-883. (Pubitemid 26107345)
2. Coward R, Foster RR, Patton D, et al., Nephrotic plasma alters slit diaphragm-dependent signalling and translocates nephrin, podocin and CD2 associated protein in cultured human podocytes. J Am Soc Nephrol 2005: 16: 629-637. (Pubitemid 41725099)
3. Pradhan M, Petro J, Palmer J, et al., Early use of plasmapheresis for recurrent post-transplant FSGS. Pediatr Nephrol 2003: 18: 934.
4. Matalon A, Markowitz GS, Joseph RE, et al., Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients. Clin Nephrol 2001: 56: 271-278. (Pubitemid 32923160)
5. Pardon A, Audard V, Caillard S, et al., Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrol Dial Transplant 2006: 21: 1053-1059.
6. Masutani K, Katafuchi R, Ikeda H, et al., Recurrent nephrotic syndrome after living-related renal transplantation resistant to plasma exchange: Report of two cases. Clin Transplant 2005: 19 (S14): 59-64. (Pubitemid 40990683)
7. Hristea D, Hadaya K, Marangon N, et al., Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 2007: 20: 102-105.
8. Gossmann J, Scheuermann EH, Porubsky S,. Abrogation of nephrotic proteinuria by rituximab treatment in renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl Int 2007: 20: 558-560.
9. Yabu JM, HO B, Scandling JD, Vincenti F,. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 2008: 8: 222-227.
10. Pirruccello SJ, Johnson D,. Reagents for flow cytometry: Monoclonal antibodies and hematopoietic cell antigens. In:, Keren DF, Hanson CA, Hanson PE, eds. Flow Cytometry and Clinical Diagnosis. Chicago, IL: ASCP, 1994: pp. 56-91.
11. Johnson PW, Glennie M,. Rituximab: Mechanisms and applications. Br J Cancer 2001: 85: 1609-1623.
12. Pescovitz MD,. Ritixumab, an anti-CD20 monoclonal antibody: History and mechanism of action. Am J Transplant 2006: 6: 859-866. (Pubitemid 44356635)
13. Guigonis V, Dallocchio A, Baudouin V, et al., Rituximab treatment for severe steroid- or cyclosporine dependent nephrotic syndrome: A multicentric series of 22 cases. Pediatr Nephrol 2008: 23: 1269-1279.
14. Ahmed MS, Wong CF,. Rituximab and nephrotic syndrome: A new therapeutic hope? Nephrol Dial Transplant 2008: 23: 11-17. (Pubitemid 351767420)
15. Bagga A, Sinha A, Moudgil A,. Rituximab in patients with steroid resistant nephrotic syndrome. N Engl J Med 2007: 356: 2751-2752. (Pubitemid 47001064)
16. Benz K, Dotsch J, Rascher W, et al., Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 2004: 19: 794-797. (Pubitemid 38931165)
17. Kamar N, Faguer S, Esposito L, et al., Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol 2007: 67: 250-254. (Pubitemid 46605375)
18. Vieira CA, Agarwal A, Book BK, et al., Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: Safety, pharmacodynamics and pharmacokinetics. Transplantation 2004: 77: 524-548.
19. Faguer S, Kamar N, Guilbeaud-Frugier C, et al., Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007: 83: 1277-1280. (Pubitemid 46743692)
20. Goldstein MJ, Lee S, Guarrera JV, et al., Rituximab rescue therapy for refractory antibody mediated rejection after kidney transplantation. Am J Transplant 2005: 5 (S11): 397-398.
21. Tyden G, Kumlien G, Genberg H, et al., ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005: 5: 145-148. (Pubitemid 40095139)
22. Meyer IN, Thaiss F, Stahl AL,. Immunoadsorption and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int 2007: 20: 1066-1069.
23. Hickson LT, Gera M, Amer H, IQBAL CW, Moore TB, et al., Kidney transplantation for primary focal segmental glomerulosclerosis: Outcomes and response to therapy for recurrence. Transplantation 2009: 87: 1232-1239.
24. Nakayama M, Kamei K, Nozu K, et al., Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 2008: 23: 481-485.
25. Cravedi P, Ruggenenti P, Sghirlanzoni M, Remuzzi G,. Table titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007: 2: 932-937.
26. Dello Strologo L, Guzzo I, Laurenzi C, et al., Use of rituximab in focal segmental glomerulosclerosis relapses after renal transplantation. Transplantation 2009: 88: 417-420.
27. Savin VJ, Mccarthy E, Sharma R, Sharma D, Sharma M,. Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res, 2008: 151: 288-292.
28. De Smet E, Rioux J-P, Ammann H, Deziel C, Querin S,. FSGS permeability factor-associated nephrotic syndrome: Remission after galactose therapy. Nephrol Dial Transplant 2009: 24: 2938-2940.